Travere Therapeutics (TVTX) Set to Announce Quarterly Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is set to issue its quarterly earnings data after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($0.87) per share for the quarter.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Monday, May 6th. The company reported ($1.76) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.78). The company had revenue of $41.40 million during the quarter, compared to analysts’ expectations of $43.46 million. Travere Therapeutics had a negative return on equity of 238.06% and a negative net margin of 87.94%. Travere Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.27) EPS. On average, analysts expect Travere Therapeutics to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Travere Therapeutics Stock Up 2.1 %

TVTX traded up $0.21 on Friday, reaching $9.98. The company’s stock had a trading volume of 66,185 shares, compared to its average volume of 1,222,831. The stock has a market cap of $759.78 million, a price-to-earnings ratio of -4.75 and a beta of 0.77. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $17.57. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. The business’s 50 day moving average is $7.97 and its 200 day moving average is $7.76.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TVTX shares. Canaccord Genuity Group increased their price target on Travere Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Travere Therapeutics in a research report on Tuesday, May 7th. Finally, Wedbush reiterated an “outperform” rating and set a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $14.64.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.